Kevin Furet - Auxly Cannabis Chief Officer
| CBWTF Stock | USD 0.03 0 3.70% |
Insider
Kevin Furet is Chief Officer of Auxly Cannabis Group
| Phone | 647 812 0121 |
| Web | https://auxly.com |
Auxly Cannabis Management Efficiency
The company has return on total asset (ROA) of (0.0868) % which means that it has lost $0.0868 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.806) %, meaning that it generated substantial loss on money invested by shareholders. Auxly Cannabis' management efficiency ratios could be used to measure how well Auxly Cannabis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robyn Sweinhart | Rezolute | N/A | |
| Antony CPA | Forte Biosciences | 57 | |
| Daniel Ryweck | Silo Pharma | 59 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Joseph Hazelton | Dyadic International | 48 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| , MBA | Molecular Partners AG | 51 | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Brian MD | Rezolute | 49 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| MD MBA | Rezolute | N/A | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| LLM JD | Rezolute | 63 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
Management Performance
| Return On Equity | -0.81 | |||
| Return On Asset | -0.0868 |
Auxly Cannabis Group Leadership Team
Elected by the shareholders, the Auxly Cannabis' board of directors comprises two types of representatives: Auxly Cannabis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Auxly. The board's role is to monitor Auxly Cannabis' management team and ensure that shareholders' interests are well served. Auxly Cannabis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Auxly Cannabis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ian Rapsey, Chief Officer | ||
| Ron Fichter, Gen Sec | ||
| Hugo Alves, President Director | ||
| Vladimir Klacar, VP Planning | ||
| Alan Cooke, VP Operations | ||
| Brian Schmitt, Chief Officer | ||
| Kevin Furet, Chief Officer | ||
| Carla Nawrocki, Vice President of Investor Relations | ||
| Andrew MacMillan, Vice President Commercial Business Development | ||
| Michael Lickver, President |
Auxly Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Auxly Cannabis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.81 | |||
| Return On Asset | -0.0868 | |||
| Profit Margin | (1.34) % | |||
| Operating Margin | (0.52) % | |||
| Current Valuation | 146.85 M | |||
| Shares Outstanding | 913.01 M | |||
| Shares Owned By Insiders | 21.04 % | |||
| Shares Owned By Institutions | 3.18 % | |||
| Price To Book | 0.18 X | |||
| Price To Sales | 0.16 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Auxly OTC Stock
Auxly Cannabis financial ratios help investors to determine whether Auxly OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Auxly with respect to the benefits of owning Auxly Cannabis security.